Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib

Leukemia

Volumn 28, Issue 4, 2014, Pages 976-977

  Mayer, K ^a   Gielen, G H ^a   Willinek, W ^a   Muller M C ^b   Wolf, D ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DASATINIB; HEPARIN; NILOTINIB; PONATINIB;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTERIOSCLEROSIS; AUTOPSY; BRAIN DEATH; BRAIN EDEMA; BRAIN INFARCTION; BRAIN ISCHEMIA; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; CORTICOSTEROID THERAPY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LETTER; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MONOSOMY 7; MOYAMOYA DISEASE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TRISOMY 8; VASCULITIS; VISUAL IMPAIRMENT;

BRAIN ISCHEMIA; FUSION PROTEINS, BCR-ABL; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84898436658     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.320     Document Type: Letter

References (8)

1. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075-2088.
2. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011; 86: 533-539.
3. Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310-1315.
4. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013; 27: 1316-1321.
5. Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347-1348.
6. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia 2013, Blood 2013; 122: 872-884.
7. Khoury HJ, Cortes JE, Kim DW, Dong-Wook K, Pinilla-Ibarz J, le Coutre P et al. Analysis of the cardiovascular risk profile of Ph\+ leukemia patients treated with ponatinib. J Clin Oncol 2013; 31(Suppl): Abstract 7048.
8. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Meyloma Leuk 2012; 12: 337-340.